Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,117 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01209156
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F] PBR111
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 25, 2026, 2:10 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Development of Novel Measures for Alzheimer's Disease Prevention Trials

NCT03900273
View directory record Official record
Conditions
Healthy Participants
Interventions
No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS), Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Manhasset, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 25, 2026, 2:10 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Brain Sleep Deprivation MRI Effects (BEDTIME)

NCT02741505
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Actigraph
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

NCT04023994
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 25, 2026, 2:10 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

NCT06268886
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
BMS-986446, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
50 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
119
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

NCT02434666
View directory record Official record
Conditions
Dementia of the Alzheimer's Type
Interventions
CPC-201
Drug
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Industry
Eligibility
50 Years to 89 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Miami, Florida • Pompano Beach, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

Pioglitazone in Alzheimer Disease

NCT00982202
View directory record Official record
Conditions
Alzheimer Disease
Interventions
pioglitazone, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Cleveland, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Negotiation Training for Caregiver Communication in AD

NCT04837937
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Impairment
Interventions
Caregiver vs. Patient [Beginner], Caregiver vs. Caregiver, Caregiver vs. Physician, Caregiver vs. Patient [Advanced]
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study

NCT01729598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 25, 2026, 2:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Synaptic Injury and Functional Connectivity in Alzheimer's Disease

NCT03300726
View directory record Official record
Conditions
Alzheimer Disease, Late Onset
Interventions
CSF analysis, Functional MRI
Diagnostic Test · Radiation
Lead sponsor
Ohio State University
Other
Eligibility
60 Years to 95 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 25, 2026, 2:10 AM EDT
Not yet recruiting Phase 2 Interventional

Terazosin And Metabolic Engagement in Alzheimer's Disease

NCT07796308
View directory record Official record
Conditions
Alzheimer s Disease
Interventions
Terazosin (Hytrin), Placebo
Drug · Other
Lead sponsor
Qiang Zhang
Other
Eligibility
50 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 25, 2026, 2:10 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia

NCT06511752
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Primary Progressive Aphasia, Aphasia, Progressive Aphasia, Progressive Aphasia in Alzheimer's Disease
Interventions
Psychosocial educational, support group and implementation of strategies
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan

NCT00788047
View directory record Official record
Conditions
Huntington Disease, Alzheimer Disease
Interventions
Dextromethorphan, Dimebon + Dextromethorphan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2009 · Synced Oct 25, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional Results available

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

NCT02322021
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Alzheimer Type
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
21
States / cities
Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

NCT00040443
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
CX516, Placebo
Drug
Lead sponsor
RespireRx
Industry
Eligibility
55 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Peoria, Arizona • Irvine, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 25, 2026, 2:10 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

NCT05738486
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Interventions
Donanemab, Placebo, Dexamethasone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
43
States / cities
Chandler, Arizona • Irvine, California • Long Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 2:10 AM EDT
Completed No phase listed Observational

Tau Imaging in Young Onset Dementia

NCT02289118
View directory record Official record
Conditions
Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia, Posterior Cortical Atrophy (PCA)
Interventions
[18F]-T807 imaging tracer
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Not applicable Interventional Results available

VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP)

NCT05379023
View directory record Official record
Conditions
Suspected Typical Alzheimer's Disease (AD), Suspected Atypical Alzheimer's Disease (AD)
Interventions
Face-to-face evaluation (FF), TeleNP evaluation
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 90 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Trial of Rifaximin in Probable Alzheimer's Disease

NCT03856359
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rifaximin 550 milligrams (MG)
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Not applicable Interventional Results available

ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease

NCT01608061
View directory record Official record
Conditions
Alzheimer Disease
Interventions
DBS-f on, DBS-f off
Device
Lead sponsor
Functional Neuromodulation Ltd
Industry
Eligibility
45 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • Sun City, Arizona • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Not applicable Interventional Results available

Assessing a Novel Virtual Environment That Assists With Activities of Daily Living

NCT05418296
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Neurodegenerative Diseases
Interventions
A novel digital health device
Device
Lead sponsor
mandy
Industry
Eligibility
Up to 110 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Elk Grove, California • Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 25, 2026, 2:10 AM EDT
Withdrawn Not applicable Interventional

Health-eBrain Study

NCT02903862
View directory record Official record
Conditions
Depression and Burden in Caregivers
Interventions
Mindoula, DANA
Behavioral · Device
Lead sponsor
AnthroTronix, Inc.
Industry
Eligibility
45 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 25, 2026, 2:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Screening for Memory Studies

NCT01123018
View directory record Official record
Conditions
Memory Loss, Memory Deficits, Dementia, Alzheimer Disease
Interventions
Memtrax Memory screening test
Behavioral
Lead sponsor
John Wesson Ashford Jr
Federal
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 25, 2026, 2:10 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Cholinergic Health After Menopause (CHAMP)

NCT04129060
View directory record Official record
Conditions
Postmenopausal Symptoms, Aging, Alzheimer Disease
Interventions
Cholinergic antagonist
Drug
Lead sponsor
University of Vermont
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 2:10 AM EDT